Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Eylea
|
| gptkbp:activities |
VEGF inhibitor
|
| gptkbp:appointed_by |
intravitreal injection
|
| gptkbp:approves |
gptkb:2011
gptkb:FDA |
| gptkbp:clinical_trial |
Phase III
ophthalmology 100% (intravitreal) |
| gptkbp:developed_by |
gptkb:Regeneron_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
aflibercept
|
| gptkbp:indication |
diabetic retinopathy
retinal vein occlusion wet AMD |
| gptkbp:ingredients |
C_63 H_88 N_16 O_18 S_4
|
| gptkbp:invention |
patented
|
| gptkbp:is_atype_of |
S01 L A05
|
| gptkbp:is_used_for |
treatment of diabetic macular edema
treatment of diabetic retinopathy treatment of neovascular age-related macular degeneration treatment of macular edema following retinal vein occlusion |
| gptkbp:lifespan |
4.5 days
|
| gptkbp:manager |
intravitreal
|
| gptkbp:marketed_as |
gptkb:physicist
|
| gptkbp:monitors |
0 A2 D1 B1 D1 A
|
| gptkbp:packaging |
single-use vial
|
| gptkbp:research |
cardiology
neurology oncology rheumatology dermatology infectious diseases immunology urology gastroenterology pulmonology |
| gptkbp:safety_features |
risk of endophthalmitis
risk of retinal tear risk of systemic thromboembolic events |
| gptkbp:side_effect |
retinal detachment
cataract increased intraocular pressure intraocular inflammation hemorrhage |
| gptkbp:storage |
2 to 8 ° C
|
| gptkbp:traded_on |
gptkb:Eylea
|
| gptkbp:type_of |
864125-63-0
|
| gptkbp:weight |
115 k Da
|